l General Information |
Product Name | Budesonide |
General description | Budesonide is a glucocorticoid used in the management of asthma, the treatment of various skin disorders, and allergic rhinitis. |
Synonym | 16,17-Butylidenebis(oxy)-11,21-dihydroxypregna-1,4-diene-3,20-dione |
Purity | ≥98%(HPLC) | CAS Number | 51333-22-3 |
Formula | C25H34O6 | Molecular Weight | 430.53 |
Suitability | BioReagent, suitable for cell culture, etc. |
l Physical and Chemical Information |
Appearance | White or Off-white solid |
Solubility(25℃) | DMSO | ≥50mg/mL |
Ethanol | ≥15mg/mL |
Water | Insoluble |
l Biological Information |
Biochem/Physiol Actions | Budesonide has a high glucocorticoid effect and a weak mineralocorticoid effect. It binds to the glucocorticoid receptor with a higher binding affinity than cortisol and prednisolone. When budesonide is systemically administered, suppression of endogenous cortisol concentrations and an impairment of the hypothalamus-pituitary-adrenal (HPA) axis function has been observed. Furthermore, a decrease in airway reactivity to histamine and other entities has been observed with the inhaled formulation. Generally, the inhaled formulation has a rapid onset action and improvement in asthma control can occur within 24 hours of initiation of treatment. |
Application | 1. Glucocorticoids 2. Bronchodilator Agents 3. Anti-Inflammatory Agents |
l Packaging & Storage |
Packaging | 250mg; 1g |
Storage temp. | 0-5℃ |
l Precautions and Disclaimer |
This product is for R&D use only, not for drug, household, or other uses. |
l References |
1. http://www.drugbank.ca 2. https://ncit.nci.nih.gov 3. https://www.ncbi.nlm.nih.gov |
